Parkinson's disease (PD) is the second most common neurological disorder, affecting approximately 4.1m people worldwide. As the prevalence rate of PD is set to rise significantly in the coming years, clinical interventions will play a major role in combating the wide spectrum of unmet needs associated with the disease.
In 2006, the global sales of PD therapeutics were $3.1bn up by 11% from $2.5bn in 2005. Revenues of the only approved PD drugs across the major markets (US, Japan, France, Germany, Italy, Spain and the UK) totaled over $2.2bn in 2006, with revenues expected to exceed $4.6bn by 2012. With key some PD drugs expected to lose patent expiration in the near-term, visiongain predicts that the entry of new products will be inevitable. But which products will be successful and how much revenue will they generate? This report tells you – order your copy today.
The report analysis PD sales over the next 15 years and delivers the percentage market growth. The projected revenue growth will be driven largely by reformulations that will decrease the burden of polypharmacy in patients receiving PD pharmacotherapy. The leading therapeutics expected to change the PD market dynamics will include, GlaxoSmithKline's (GSK's) Requip Once-daily ER awaiting approval, UCB-Schwarz's Neupro, Teva and Lundbeck’s Azilect. How will these products effect you and your business? Find out today.
Other key compounds predicted for success include Kyowa Hakko’s Istradefylline, Merck-Serono/Newron’s Safinamide. The new wave of Gene/cell Therapy compounds that have revealed positive initial clinical data, thus Neurotrophic growth factors (NGF), either to be injected directly into the brain are also tipped for potential market success. Ceregene’s Neuturine, Neurologix’ GAD (glutamic acid decarboxylase) amongst other similar drugs, will add to the present PD therapeutics that will expand revenue growth in the long-term.
With country-by-country focus on the markets of:
- US
- UK
- Germany
- Japan
- France
- Italy
- Spain
This report includes detailed five-year forecasts over the period 2008-2012, and NOW features 10 and 15 year forecasts to help you understand the medium-term prospects for these markets.
Why You Must Buy This Report:
This report features tables, graphs and charts, news, insights, the past and present developments in Market. This report will provide you with the complete understanding of the demand for a shift from modest therapies to highly efficacious drugs for the treatment of PD.
This visiongain report is the single authoritative and in-depth tool to equip you with the latest trends in all regional markets and why all (stakeholders) demand a new generation of drugs to improve the quality of live of suffers of PD and their caregivers. Visiongain recommends this astute and hard-hitting report with detailed information into the key market development and major players in the field.
Parkinson’s Disease Market Analysis & Forecasts 2008-2022 report is a must buy, because it presents in-depth and unbiased financial analysis for the near-term, medium-term and the long-term, market dynamics. When you buy the Visiongain 2008 PD report, you will be buying current and vital information on the vast array of compounds in pipeline that are marked for potential success in the long-term treatment of AD.
Unique benefits to you when you order this report:
- Primary research throughout. You will not find this information anywhere else
- Report stored in your reading room for ever
- Full searchable report when you buy the company or corporate editions
- Copies can be printed off for offline reading
- Packed with charts, analysis, figures, graphs and tables
What questions does the report answer?
• Which regions have the highest prevalence of AD diseases today?
• Do you know the cost of PD across the larger markets?
• Who are the market leaders in this class of therapy?
• What market share was accounted for by the leading drugs in the major markets?
• Do you know how much the PD market will be worth by Q4 of 2007 and its potential value by 2012, 2017 and 2022?
• Which first line drugs will be coming off patent by 2012 and what are the economic implications to the market?
• Do you know the market Potential of Teva/Lundbeck’s Azilect?
• Do you know the Neuroprotective properties of Gene/cell Therapy compounds?
• Do you know which drugs have been withdrawn from the neurodegenerative market?
• Which molecules are currently in the PD pipelines that are deemed to answer unmet therapeutic needs in the future?
Global Therapy Industry
Chapter 1
Executive Summary
Chapter 2
Introduction To Parkinson’s Disease (PD)
2.1 Parkinson's Disease Overview
2.2 Pathophysiology Of PD
2.3 Types Of Age-Related Parkinson's Disease
2.4 Parkinson's Disease Rating Scale
2.5 Etiology of Parkinson's Disease
2.6 What are the Risk Factors?
2.6.1 Age
2.6.2 A possible Genetic Basis To PD
2.6.3 Men Are More Likely To Develop PD
2.6.4 Pesticides And Herbicides Influence PD Development
2.6.5 Reduced Oestrogen Levels Increase The Risk Of PD
2.6.6 Reduced Folate Levels Associated With PD
2.6.7 Anti-Oxidants
2.7 Initial Presentation Of PD
2.7.1 Tremors
2.7.2 Rigidity
2.7.3 Akinesia
2.7.4 Postural Instability
2.7.5 Comobidities Of PD
2.7.5.1 Sleep Disturbances In PD
2.7.5.2 Dementia
2.7.5.3 Depression
2.7.5.4 Sexual Dysfunction
2.7.5.5 Emotional Disturbances
2.7.5.6 Weight Loss
2.7.5.7 Shortness Of Breath
2.7.5.8 Visual Impairment
2.7.5.9 Potential Risk of Falling
2.7.5.10 Other Autonomic Nervous System Disturbances
2.8 Symptoms Of PD
2.9 Diagnosis Of PD
2.9.1 Proven Diagnostic Criteria For PD
2.9.1.1 Neurological Evaluation Of PD
2.9.1.2 Laboratory Evaluation Of PD
2.9.1.3 Imaging Studies For PD
2.10 Prognosis Of PD- Hoenn And Yahr Scale
2.11 Demographics Of PD (Incidence And Prevalence)
2.12 Financial Burden Of PD
Chapter 3
Pharmacotherapy for PD
3.1 Current Pharmaceutical Therapies Of PD
Available In The PD Market
3.2 Classes Of Drugs Available In The PD Market
3.3 Dopamine Precursors As The Standard Treatments For PD
3.3.1 Side-Effects Of Levodopa
3.4 Dopamine Agonists As Treatments For PD
3.4.1 Requip (Ropinirole)
3.4.2 Sifrol/Mirapexin (Pramipexole) a Dopamine D2 Agonist Is The Leading PD Drug
3.4.3 Parlodel (Bromocriptine)
3.4.4 Dopergine (Lisuride) Is Superior To Parlodel
3.4.5 Permax (Pergolide)
3.4.6 Side-Effects Of Dopamine Agonist
3.5 Monoamine Oxidase B Inhibitors ((MAO-B)
3.5.1 Deprenyl (Selegeline)
3.5.1.1 Side Effects Of Selegeline
3.5.2 Rasagiline (Azilect)
3.6 COMT (Catechol-O-Methyl Transferase) Inhibitors
3.6.1 Tasmar (Tolcapone) As An Adjunct Therapy
3.6.2 Comtess (Entacapone) To Aid PD Treatment
3.7 Dopamine And COMT Combined
3.7.1 Stalevo The Combination Therapy
3.8 Anticholinergics (Antimuscarinic drugs)
3.8.1 Congentin (Benzatropine Mesilate)
3.8.2 Artane (Trihexyphenidyl) To Control Common Symptoms
3.9 Antihistamines And Antidepressants Can Aid PD Symptoms?
3.10 Apomorphine as Additional Relief for PD Sufferers
3.11 N-Methyl-D-Asparate Receptor Antagonists (NMDA)
3.12 Antiviral Drugs -Symmetrel (Amantadine)
3.13 Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Receptor Antagonist
3.13.1 Talampanel
3.14 Parkinson's Patch Approved In Europe For All Stages Of Parkinson's Disease
3.15 Novartis' Exelon Alzheimer's Drug For PD
3.16 Surgical Therapy Is Not a Popular Treatment Of PD
3.16.1 Thalamotomy Only Used To Reduce Tremors
3.16.2 Pallidotomy Is Becoming More Popular As A Treatment For PD
3.17 Medtronic Activa Therapy Survey
Chapter 4
Parkinson’s Disease World Market Analysis
4.1 The World Market For PD Drugs Will Show Significant Growth To 2012
4.2 PD Sales Revenues
4.3 Sifrol /Mirapex (pramipexole) The Leading Dopamine Agonists for PD
4.4 Successful 50-month Study Positions Mirapex As First-Line Drug For PD In EU
4.5 Sifrol And Other Newer Products Reclaim Market Share From Anticholinergics And L-Dopa Generics
4.6 Sifrol Gradually Losing Market Share To GSK's Requip
4.7 FDA Accepts GSK/SkyePharma Once-Daily Requip (Ropinirole HCl) XL 24-Hour Extended-Release Tablets
4.8 key Findings Supporting Success of Requip
4.9 Requip Experiences Continuous Sales Growth
4.10 Pfizer's Cabaser/Dostinex (Cabergoline) Outperformed By Sifrol
4.11 Dopaminergic Market
4.11.1 Sinemet (Co-Careldopa)
4.11.2 Madopar (Co-benelopa)
4.11.3 Carbidopa and Benserazide
4.11.4 Monoamine Oxidase B Inhibitor-Azilect (Rasagiline)
4.12 The TEMPO Study-Rasagiline In Early PD
4.12.1 The TEMPO Extended Study
4.12.2 The PRESTO And LARGO Studies - Rasagiline In Moderate-To-Advanced PD
4.13 Azilect With Potential To See Significant Revenue Growth
4.14 Comtan (Entacapone) Leading COMT Inhibitors Captures Tasmar's Market Share
4.15 Orions’ Comtess
4.16 Stalevo Combination Therapy Drives Sales Growth
Chapter 5
Major Market Analysis
5.1 Major Markets Experience Year-on-Year Revenue Expansions
5.2 The US Is the Largest PD Market
5.3 Japan Experience Sales Decline In 2006
5.4 EU PD Profit Margins Exceed The US
5.5 Germany Leads The EU Markets
5.6 The UK Market Experienced The Smallest Revenue Growth In 2006
5.7 France PD Pharmaceutical Revenue Growth Expands
5.8 Rising Sales Growth In Italian PD Market
5.9 Spain Experiences Highest Growth in EU PD Market in 2006
Chapter 6
Experts' Views on Main Issues in the Treatment of PD
6.1 The Most Important Unmet Medical Needs In The Treatment of Parkinson’s Disease (PD)
6.2 Which Drugs Will Be Central Part Of Treatment For Between Now And 2020?
6.3 Do You Think That The Present Drugs Are Cost-effective?
6.4 Will Public And Private Healthcare In EU And Drugs For The Treatment Of PD?
6.5 What Is The Current Market Valuation For PD Drugs?
6.6 Do You Think Compounds That Can Deliver Neuroprotection Will Change The Dynamics Of The PD Market?
6.7 Are There Any Products In The Pipeline That Will Change The Market - Which Ones And Why Do You Think So?
6.8 How Quickly Will This Market Grow Once A Wider Range Of Drugs is Introduced?
6.9 Which Companies Do You Think Will Become Involved In This Market, And Make A Significant Impact?
6.10 Do You Think Through Gene Therapy Has A Place In The Treatment Of PD?
6.11 Concluding Thoughts
Chapter 7
Pipeline Developments In Parkinson's Treatment
7.1 The Scope Of PD Pipeline
7.2 Emerging Therapies For Parkinson's Disease
Small Molecule Drugs
7.2.1 ALS Drug, Rilutek (Riluzole), To Help PD Patients
7.2.2 HD Treatment, Remacemide (Remacemide hydrochloride), For PD
7.3 Other New Drugs in Development
7.3 .1 Wyeth And Curis Hedgehog Signalling Pathway Research Potential For Neurodegenerative Diseases
7.3.2 The Process Of Apoptosis In Parkinson's Disease
7.3.3 Pig Neuron Implantations As New Treatments For PD
7.3.4 A Nerve Growth Promoter May Have a Role In PD Treatment
7.3.5 The Implantation Of Dopamine Producing Cells As A Novel Therapy In PD
7.3.6 GDNF Gene Therapy As A New Treatment Therapy
7.3.7 Biogen Idec And Vernalis Phase II BIIB014 oral Compound
7.3.8 Subcutaneous Drug Delivery System Underway For Treatment Of PD
7.3.9 Neuroprotective Agent PD 02 Slows PD Progression In Phase II Trials
7.3.10 Merck Serono And Newron's Safinamide Effective In Early And Late-Stage Parkinson's Disease
7.3.11 Signalling Ret-Receptors Protect The Live Of Nerve Cells In The Aging Brain
7.3.12 Kyowa Hakko Istradefylline (KW- 6002)
7.3.13 Neurologix Completes Phase I GAD Gene Therapy Trial For Parkinson's Disease.
7.3.14 Ceregene In A Phase II Neurturin Gene Therapy Study
7.3.15 Arundic Acid An Astrocyte Modulating Agent For PD
7.3.16 Antioxidative Properties Of Vitamin E, C And Health Food
7.3.17 Coenzyme Q10 as a potential antioxidant
7.3.18 Alseres Pharmaceuticals Altropane PD Diagnostic Tool For PD
Chapter 8
Global AD Pharmaceutical & Healthcare Industry SWOT Analysis
8.1 SWOT Analysis Of The Parkinson's Disease Market
8.2 Unmet Medical Needs For PD
8.3 Patient Potential To Drive Anti-PD Market
8.4 Major Restraints Of The PD Market
8.5 Patient Focus Or Drug Focus?
8.6 Patients To Bear Cost Of Increasing Regulatory Requirements
8.7 More Focus On Patients During Clinical Studies
8.8 Generic Competition
8.9 Technology Transfer in PD
8.10 Leading Drugs Still Carry Motor Complications
8.11 Teva And Lundbeck's Azilect To Lead The Way In Future Therapy
8.12 Biomarker and Pharmacogenetics
8.13 Potential Application Of Biomarkers And Pharmacogenetic (Pharmacogenomics)
8.14 High Return-On-Investment In PD Market
8.15 Cost-effective Analysis Will Be A Potential Threat For Reimbursement
8.15.1 Controversy Over NICE’s Decisions
8.15.2 Will CEA Be Disincentive To R&D?
8.16 Reformulation Of Drugs To Drive Revenue Growth
8.17 Schwarz Pharma PD Transdermal Patch To Reduce Polypharmacy
8.18 Impact Of Parkinson's Disease Will Continue To Stretch Healthcare Budget Until when Pharmacological Agents Are Able To Address Unmet Needs
8.19 Pallidotomy Is Becoming More Popular As A Treatment For PD
8.20 Change Of Patients And Physician Attitude Will Be Essential For Growth Of PD Market
Chapter 9
Conclusion
9.1 Global Market Will Experience Sustained Revenues Markets Set To Experience Rise In Revenue Growth
9.2.1 The US PD Revenue Growth Champions Other Markets
9.2.2 Japan To Experience Slow Revenue Growth
9.2.3 EU PD Profit Margins Exceed US
9.2.4 Germany Leads The EU PD Markets
9.2.5 The UK Market Experienced The Smallest PD Revenue Growth in 2006
9.2.6 France PD Pharmaceutical Revenue Growth Expands
9.2.7 Rising Sales Growth In Italian PD Market
9.2.8 Spain Experiences Highest Growth In EU PD Market
9.3 Rising Patient Potential and Improved Therapeutics Will Drive PD Global Revenue Growth
9.4 Promising R&D Pipeline
List of Tables
Table 1.1. PD Global and Regional Revenue Forecast ($m) 2007-2012,2017 & 2022
Table 1.2 Patent Expiration on Leading anti-Parkinson’s Drugs
Table 1.3. Prevalence of Parkinson’s Disease Accross The Seven Major Markets (2006)
Table 2.1 Factor that may influence Parkinson’s Disease
Table 2.2 Prognosis of PD by Hoehn and Yahr scale
Table 4.1 Global PD Market Forecast ($m),2007-2012,2017 & 2022
Table 4.2 The Global Parkinson’s disease Market,2004-2006
Table 4.3 Sifrol Global Sale Forecast ($m),2007,2017 & 2022
Table 4.4 Requip Global Sale Forecast ($m),2007,2017 & 2022
Table 4.5 Cabaser Global Sale Forecast ($m),2007,2017 & 2022
Table 4.6 Sinemet Global Sale Forecast ($m),2007,2017 & 2022
Table 4.7 Madopar Global Sale Forecast ($m),2007,2017 & 2022
Table 4.8 Azilect Global Sale Forecast ($m),2007,2017 & 2022
Table 4.9 Comtan Global Sale Forecast ($m),2007,2017 & 2022
Table 4.10 Stalevo Global Sale Forecast ($m),2007,2017 & 2022
Table 5.1 Sales ($m) of Leading PD drugs in the US Market,2004-2006
Table 5.2 US PD Sales Forecast ($m),2007,2017 & 2022
Table 5.3 Sales ($m) of Leading PD drugs in the Japanese Market,2004-2006
Table 5.4 Japan PD Sales Forecast ($m),2007,2017 & 2022
Table 5.5 Regional Annual PD Revenues ($m),2005-2006
Table 5.6 Regional PD Revenues ($m),2005-2006
Table 5.7 Sales ($m) of Leading PD drugs in the Japanese Market,2004-2006
Table 5.8 Germany PD Sales Forecast ($m),2007,2017 & 2022
Table 5.9 Sales ($m) of Leading PD drugs in the UK Market,2004-2006
Table 5.10 UK PD Sales Forecast ($m),2007,2017 & 2022
Table 5.11 Sales ($m) of Leading PD Drugs in France,2005-2006
Table 5.12 France PD Sales Forecast ($m),2007,2017 & 2022
Table 5.13 Sales ($m) of Leading PD Drugs in Italy,2005-2006
Table 5.14 Italy PD Sales Forecast ($m),2007,2017 & 2022
Table 5.15 Sales ($m) of Leading PD Drugs in Italy,2005-2006
Table 5.16 Spain PD Sales Forecast ($m),2007,2017 & 2022
Table 7.1 Parkinson’s disease Pipeline,2006
Table 8.1 SWOT Analysis of the Parkinson’s disease Market
Table 8.2 Economic Evaluation in EU Major Markets, 2006
Table 8.3 Economic Evaluation in EU Major Markets 2006
List of Charts
Chart 1.1. PD Global Revenue Forecast ($m) 2007-2012,2017 & 2022
Chart 1.2. PD Regional Revenue Forecast ($m) 2007-2012,2017 & 2022
Chart 1.3. Deomographics of Parkinson’s Disease Across Major Markets,2006
Chart 4.1 The Global Parkinson’s disease Market,2004-2006
Chart 4.2 The Global Parkinson’s disease Drugs Market Share, 2006
Chart 4.3 Sifrol Global Sales ($m) 2003-2006
Chart 4.4 Sifrol Global Sale Forecast ($m),2007,2017 & 2022
Chart 4.5 Requip Global Sales ($m) 2003-2006
Chart 4.6 Requip Global Sale Forecast ($m),2007,2017 & 2022
Chart 4.7 Cabaser Global Sales ($m) 2003-2006
Chart 4.8 Cabaser Global Sale Forecast ($m),2007,2017 & 2022
Chart 4.9 Sinemet Global Sales ($m),2003-2006
Chart 4.10 Sinemet Global Sale Forecast ($m),2007,2017 & 2022
Chart 4.11 Madopar Global Sales ($m), 2003-2006
Chart 4.12 Madopar Global Sale Forecast ($m),2007,2017 & 2022
Chart. 4.13 Azilect Global Sale Forecast ($m),2007,2017 & 2022
Chart 4.14 Comtan Global Sales ($m),2003-2006
Chart 4.15 Comtan Global Sale Forecast ($m),2007,2017 & 2022
Chart 4.16 Comtess Global Sales ($m),2003-2006
Chart 4.17 Stalevo Global Sales ($m),2003-2006
Chart 4.18 Stalevo Global Sale Forecast ($m),2007,2017 & 2022
Chart 4.19 Global PD Market Forecast ($m),2007-2012,2017 & 2022
Chart 5.1 Market Share of Leading PD drugs in the US Market,2004-2006
Chart 5.2 US PD Sales Forecast ($m),2007,2017 & 2022
Chart 5.3 Market Share of Leading PD drugs in Japan,2006
Chart 5.4 Japan PD Sales Forecast ($m),2007,2017 & 2022
Chart 5.5 Market Share of PD Revenues ($m), 2006
Chart 5.6 Market Share of Major EU PD markets
Chart 5.7 Market Share of Leading PD drugs in Germany,2006
Chart 5.8 Germany PD Sales Forecast ($m),2007,2017 & 2022
Chart 5.9 Market Share of leading PD drugs in the UK,2006
Chart 5.10 UK PD Sales Forecast ($m),2007,2017 & 2022
Chart 5.11 Market Share of PD Drugs in France 2006
Chart 5.12 France PD Sales Forecast ($m),2007,2017 & 2022
Chart 5.13 Market Share of PD Drugs in Italy 2006
Chart 5.14 Italy PD Sales Forecast ($m),2007,2017 & 2022
Chart 5.15 Market Share of PD Drugs in Spain, 2006
Chart 5.16 Spain, PD Sales Forecast ($m),2007,2017 & 2022
Chart 8.1 Unmet need at Early Stages of Parkinson’s disease
Chart 8.2 Unmet need at Late Stages of Parkinson’s disease
Chart 8.3 Spectrum of Present Unmet needs in PD management
Chart 8.4 Significant Factors to Driveb Revenue Growth of PD Market
Chart 8.5 Restraining factors to Potential Revenue growth of PD Market
Companies and Organisations
Abbott
Aeolus
Alliance
Alseres
Amarin
Amgen
Antipodean
AstraZeneca
Avicena
Avigen
Bar
BarIlan University
Biogen Idec
Biomas
Boehringer Ingelheim
BristolMyersSquib
Britannia
Cell Genesys
Ceregene
Dainippon Sumitomo
Diamyd Medical
Eisai
Elan
Eli Lily
Faust Pharmaceutical
Forest
Fujomo
Genzyme
Georgetown University
Guilford
Juvantia
Kyowa Hakko
Lederle
Lunbeck
Max Planck Institute of Neurobiology
Medtronic
Meiji Seika
Merck KGaA
Merck Serono
Mertz
Merz
Mylan
National Patent Development
Neuren
Neurobiotics
NeuroCell
Neurologix
Newron
Novartis
ONO
Orion
Pfizer
Pharmaplaz
Phytrix
Prestwick
Roche
Samaritan
Sanofi-Aventis
Santhera
Schering-Plough
Schwarz Pharma
Scientific Testing
Siegfried
SkyePharma
Solvay
Syngis
The National Institute of Neurological Disorder and Stokes (NINDS
The New England Journal of Medicine
Valeant
Vernalis
Wyeth
